{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T06:52:17Z","timestamp":1793429537285,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T00:00:00Z","timestamp":1729987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T00:00:00Z","timestamp":1729987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-024-00822-y","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T04:42:45Z","timestamp":1730090565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Structural basis of epitope recognition by anti-alpha-synuclein antibodies MJFR14-6-4-2"],"prefix":"10.1038","volume":"10","author":[{"given":"Ilva","family":"Liekni\u0146a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodors","family":"Pante\u013cejevs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alons","family":"Lends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristaps","family":"Jaudzems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aadil","family":"El-Turabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hjalte","family":"Gram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa","family":"Hammi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poul Henning","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaspars","family":"T\u0101rs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,27]]},"reference":[{"key":"822_CR1","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.neuron.2013.09.004","volume":"79","author":"JT Bendor","year":"2013","unstructured":"Bendor, J. T., Logan, T. P. & Edwards, R. H. The function of alpha-synuclein. Neuron 79, 1044\u20131066 (2013).","journal-title":"Neuron"},{"key":"822_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41531-023-00444-w","volume":"9","author":"N Ramalingam","year":"2023","unstructured":"Ramalingam, N. et al. Dynamic physiological alpha-synuclein S129 phosphorylation is driven by neuronal activity. NPJ Parkinsons Dis. 9, 4 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"822_CR3","doi-asserted-by":"publisher","first-page":"32701","DOI":"10.1073\/pnas.2013652117","volume":"117","author":"M Somayaji","year":"2020","unstructured":"Somayaji, M. et al. A dual role for alpha-synuclein in facilitation and depression of dopamine release from substantia nigra neurons in vivo. Proc. Natl Acad. Sci. USA 117, 32701\u201332710 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"822_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi, P. et al. Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 14, 176 (2023).","journal-title":"Cell Death Dis."},{"key":"822_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. Alpha-synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"822_CR6","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/j.1440-1789.2007.00803.x","volume":"27","author":"K Wakabayashi","year":"2007","unstructured":"Wakabayashi, K. et al. The Lewy body in Parkinson\u2019s disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27, 494\u2013506 (2007).","journal-title":"Neuropathology"},{"key":"822_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel, H. A. et al. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38\u201348 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"822_CR8","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1126\/science.1090439","volume":"302","author":"TF Outeiro","year":"2003","unstructured":"Outeiro, T. F. & Lindquist, S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302, 1772\u20131775 (2003).","journal-title":"Science"},{"key":"822_CR9","doi-asserted-by":"publisher","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","volume":"2","author":"L Stefanis","year":"2012","unstructured":"Stefanis, L. alpha-Synuclein in Parkinson\u2019s disease. Cold Spring Harb. Perspect. Med. 2, a009399 (2012).","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"822_CR10","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.bbadis.2008.07.006","volume":"1792","author":"KA Jellinger","year":"2009","unstructured":"Jellinger, K. A. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys. Acta 1792, 730\u2013740 (2009).","journal-title":"Biochim Biophys. Acta"},{"key":"822_CR11","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/brain\/awz030","volume":"142","author":"RB Postuma","year":"2019","unstructured":"Postuma, R. B. et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 142, 744\u2013759 (2019).","journal-title":"Brain"},{"key":"822_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneurol.2014.226","volume":"11","author":"D Athauda","year":"2015","unstructured":"Athauda, D. & Foltynie, T. The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat. Rev. Neurol. 11, 25\u201340 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"822_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.expneurol.2017.10.003","volume":"298","author":"P Brundin","year":"2017","unstructured":"Brundin, P., Dave, K. D. & Kordower, J. H. Therapeutic approaches to target alpha-synuclein pathology. Exp. Neurol. 298, 225\u2013235 (2017).","journal-title":"Exp. Neurol."},{"key":"822_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira, A. H. V., Chaudhuri, K. R. & Jenner, P. Non-motor features of Parkinson disease. Nat. Rev. Neurosci. 18, 435\u2013450 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"822_CR15","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/mds.27090","volume":"32","author":"B Mollenhauer","year":"2017","unstructured":"Mollenhauer, B. et al. A user\u2019s guide for alpha-synuclein biomarker studies in biological fluids: Perianalytical considerations. Mov. Disord. 32, 1117\u20131130 (2017).","journal-title":"Mov. Disord."},{"key":"822_CR16","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1093\/brain\/awz104","volume":"142","author":"CW Olanow","year":"2019","unstructured":"Olanow, C. W. et al. Temporal evolution of microglia and alpha-synuclein accumulation following foetal grafting in Parkinson\u2019s disease. Brain 142, 1690\u20131700 (2019).","journal-title":"Brain"},{"key":"822_CR17","doi-asserted-by":"publisher","first-page":"e0196056","DOI":"10.1371\/journal.pone.0196056","volume":"13","author":"LB Lassen","year":"2018","unstructured":"Lassen, L. B. et al. ELISA method to detect alpha-synuclein oligomers in cell and animal models. PLoS One 13, e0196056 (2018).","journal-title":"PLoS One"},{"key":"822_CR18","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.3390\/cells11223673","volume":"11","author":"LB Lassen","year":"2022","unstructured":"Lassen, L. B. et al. Mutation of Tyrosine Sites in the Human Alpha-Synuclein Gene Induces Neurotoxicity in Transgenic Mice with Soluble Alpha-Synuclein Oligomer Formation. Cells 11, 3673 (2022).","journal-title":"Cells"},{"key":"822_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04422-2","volume":"9","author":"MHR Ludtmann","year":"2018","unstructured":"Ludtmann, M. H. R. et al. alpha-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson\u2019s disease. Nat. Commun. 9, 2293 (2018).","journal-title":"Nat. Commun."},{"key":"822_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00401-021-02316-0","volume":"142","author":"N Ferreira","year":"2021","unstructured":"Ferreira, N. et al. Multiple system atrophy-associated oligodendroglial protein p25alpha stimulates formation of novel alpha-synuclein strain with enhanced neurodegenerative potential. Acta Neuropathol. 142, 87\u2013115 (2021).","journal-title":"Acta Neuropathol."},{"key":"822_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00401-019-02014-y","volume":"138","author":"P Mavroeidi","year":"2019","unstructured":"Mavroeidi, P. et al. Endogenous oligodendroglial alpha-synuclein and TPPP\/p25alpha orchestrate alpha-synuclein pathology in experimental multiple system atrophy models. Acta Neuropathol. 138, 415\u2013441 (2019).","journal-title":"Acta Neuropathol."},{"key":"822_CR22","doi-asserted-by":"publisher","first-page":"e2109617119","DOI":"10.1073\/pnas.2109617119","volume":"119","author":"SS Ghanem","year":"2022","unstructured":"Ghanem, S. S. et al. alpha-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proc. Natl Acad. Sci. USA 119, e2109617119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"822_CR23","doi-asserted-by":"publisher","first-page":"827493","DOI":"10.3389\/fnagi.2022.827493","volume":"14","author":"Z Yu","year":"2022","unstructured":"Yu, Z. et al. Erythrocytic alpha-Synuclein Species for Parkinson\u2019s Disease Diagnosis and the Correlations With Clinical Characteristics. Front Aging Neurosci. 14, 827493 (2022).","journal-title":"Front Aging Neurosci."},{"key":"822_CR24","doi-asserted-by":"publisher","first-page":"105086","DOI":"10.1016\/j.nbd.2020.105086","volume":"146","author":"ST Kumar","year":"2020","unstructured":"Kumar, S. T. et al. How specific are the conformation-specific alpha-synuclein antibodies? Characterization and validation of 16 alpha-synuclein conformation-specific antibodies using well-characterized preparations of alpha-synuclein monomers, fibrils and oligomers with distinct structures and morphology. Neurobiol. Dis. 146, 105086 (2020).","journal-title":"Neurobiol. Dis."},{"key":"822_CR25","doi-asserted-by":"crossref","unstructured":"Pumpens, P. & Puskho, P. Virus-Like Particles: A Comprehensive Guide. 2022: CRC Press.","DOI":"10.1201\/b22819"},{"key":"822_CR26","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1126\/science.8248784","volume":"262","author":"MF Bachmann","year":"1993","unstructured":"Bachmann, M. F. et al. The influence of antigen organization on B cell responsiveness. Science 262, 1448\u20131451 (1993).","journal-title":"Science"},{"key":"822_CR27","doi-asserted-by":"publisher","first-page":"6211","DOI":"10.4049\/jimmunol.175.9.6211","volume":"175","author":"G Spohn","year":"2005","unstructured":"Spohn, G. et al. Protection against osteoporosis by active immunization with TRANCE\/RANKL displayed on virus-like particles. J. Immunol. 175, 6211\u20136218 (2005).","journal-title":"J. Immunol."},{"key":"822_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000449503","volume":"59","author":"P Pumpens","year":"2016","unstructured":"Pumpens, P. et al. The True Story and Advantages of RNA Phage Capsids as Nanotools. Intervirology 59, 74\u2013110 (2016).","journal-title":"Intervirology"},{"key":"822_CR29","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1016\/j.jmb.2016.08.025","volume":"428","author":"M Shishovs","year":"2016","unstructured":"Shishovs, M. et al. Structure of AP205 Coat Protein Reveals Circular Permutation in ssRNA Bacteriophages. J. Mol. Biol. 428, 4267\u20134279 (2016).","journal-title":"J. Mol. Biol."},{"key":"822_CR30","doi-asserted-by":"publisher","first-page":"e0181844","DOI":"10.1371\/journal.pone.0181844","volume":"12","author":"M Doucet","year":"2017","unstructured":"Doucet, M. et al. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles. PLoS One 12, e0181844 (2017).","journal-title":"PLoS One"},{"key":"822_CR31","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S0022-2836(03)00520-5","volume":"329","author":"R Bussell Jr.","year":"2003","unstructured":"Bussell, R. Jr. & Eliezer, D. A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. J. Mol. Biol. 329, 763\u2013778 (2003).","journal-title":"J. Mol. Biol."},{"key":"822_CR32","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1006\/jmbi.2001.4538","volume":"307","author":"D Eliezer","year":"2001","unstructured":"Eliezer, D. et al. Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 307, 1061\u20131073 (2001).","journal-title":"J. Mol. Biol."},{"key":"822_CR33","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","volume":"281","author":"JP Anderson","year":"2006","unstructured":"Anderson, J. P. et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739\u201329752 (2006).","journal-title":"J. Biol. Chem."},{"key":"822_CR34","doi-asserted-by":"publisher","first-page":"16895","DOI":"10.1074\/jbc.M800747200","volume":"283","author":"KE Paleologou","year":"2008","unstructured":"Paleologou, K. E. et al. Phosphorylation at Ser-129 but not the phosphomimics S129E\/D inhibits the fibrillation of alpha-synuclein. J. Biol. Chem. 283, 16895\u201316905 (2008).","journal-title":"J. Biol. Chem."},{"key":"822_CR35","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1177\/24725552211013827","volume":"26","author":"O Kartal","year":"2021","unstructured":"Kartal, O. et al. waveRAPID-A Robust Assay for High-Throughput Kinetic Screens with the Creoptix WAVEsystem. SLAS Discov. 26, 995\u20131003 (2021).","journal-title":"SLAS Discov."},{"key":"822_CR36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jmb.2010.07.001","volume":"402","author":"EJ De Genst","year":"2010","unstructured":"De Genst, E. J. et al. Structure and properties of a complex of alpha-synuclein and a single-domain camelid antibody. J. Mol. Biol. 402, 326\u2013343 (2010).","journal-title":"J. Mol. Biol."},{"key":"822_CR37","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1110\/ps.3180102","volume":"11","author":"Y Wang","year":"2002","unstructured":"Wang, Y. & Jardetzky, O. Probability-based protein secondary structure identification using combined NMR chemical-shift data. Protein Sci. 11, 852\u2013861 (2002).","journal-title":"Protein Sci."},{"key":"822_CR38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1023\/A:1008376710086","volume":"13","author":"M Iwadate","year":"1999","unstructured":"Iwadate, M., Asakura, T. & Williamson, M. P. C alpha and C beta carbon-13 chemical shifts in proteins from an empirical database. J. Biomol. NMR 13, 199\u2013211 (1999).","journal-title":"J. Biomol. NMR"},{"key":"822_CR39","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3233\/JPD-171248","volume":"8","author":"NK Polinski","year":"2018","unstructured":"Polinski, N. K. et al. Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson\u2019s Disease in Rodents. J. Parkinsons Dis. 8, 303\u2013322 (2018).","journal-title":"J. Parkinsons Dis."},{"key":"822_CR40","doi-asserted-by":"publisher","first-page":"104912","DOI":"10.1016\/j.jbc.2023.104912","volume":"299","author":"S Quintin","year":"2023","unstructured":"Quintin, S. et al. Cellular processing of alpha-synuclein fibrils results in distinct physiological C-terminal truncations with a major cleavage site at residue Glu 114. J. Biol. Chem. 299, 104912 (2023).","journal-title":"J. Biol. Chem."},{"key":"822_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s40478-019-0865-5","volume":"7","author":"S Elfarrash","year":"2019","unstructured":"Elfarrash, S. et al. Organotypic slice culture model demonstrates inter-neuronal spreading of alpha-synuclein aggregates. Acta Neuropathol. Commun. 7, 213 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"822_CR42","doi-asserted-by":"publisher","first-page":"e0252635","DOI":"10.1371\/journal.pone.0252635","volume":"16","author":"S Elfarrash","year":"2021","unstructured":"Elfarrash, S. et al. Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein. PLoS One 16, e0252635 (2021).","journal-title":"PLoS One"},{"key":"822_CR43","doi-asserted-by":"publisher","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","volume":"34","author":"D Games","year":"2014","unstructured":"Games, D. et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson\u2019s disease-like models. J. Neurosci. 34, 9441\u20139454 (2014).","journal-title":"J. Neurosci."},{"key":"822_CR44","doi-asserted-by":"publisher","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","volume":"6","author":"E Masliah","year":"2011","unstructured":"Masliah, E. et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 6, e19338 (2011).","journal-title":"PLoS One"},{"key":"822_CR45","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.celrep.2014.05.033","volume":"7","author":"HT Tran","year":"2014","unstructured":"Tran, H. T. et al. Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration. Cell Rep. 7, 2054\u20132065 (2014).","journal-title":"Cell Rep."},{"key":"822_CR46","doi-asserted-by":"publisher","first-page":"104582","DOI":"10.1016\/j.nbd.2019.104582","volume":"132","author":"DJ Schofield","year":"2019","unstructured":"Schofield, D. J. et al. Preclinical development of a high affinity alpha-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular alpha-synuclein and attenuate alpha-synuclein spreading in vivo. Neurobiol. Dis. 132, 104582 (2019).","journal-title":"Neurobiol. Dis."},{"key":"822_CR47","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","volume":"124","author":"A Weihofen","year":"2019","unstructured":"Weihofen, A. et al. Development of an aggregate-selective, human-derived alpha-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models. Neurobiol. Dis. 124, 276\u2013288 (2019).","journal-title":"Neurobiol. Dis."},{"key":"822_CR48","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano, G. et al. Trial of Prasinezumab in Early-Stage Parkinson\u2019s Disease. N. Engl. J. Med. 387, 421\u2013432 (2022).","journal-title":"N. Engl. J. Med"},{"key":"822_CR49","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang, A. E. et al. Trial of Cinpanemab in Early Parkinson\u2019s Disease. N. Engl. J. Med. 387, 408\u2013420 (2022).","journal-title":"N. Engl. J. Med"},{"key":"822_CR50","doi-asserted-by":"publisher","first-page":"7972","DOI":"10.3390\/ijms22157972","volume":"22","author":"Z Toleikis","year":"2021","unstructured":"Toleikis, Z. et al. S100A9 Alters the Pathway of Alpha-Synuclein Amyloid Aggregation. Int J. Mol. Sci. 22, 7972 (2021).","journal-title":"Int J. Mol. Sci."},{"key":"822_CR51","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/biom12030436","volume":"12","author":"F De Giorgi","year":"2022","unstructured":"De Giorgi, F. et al. Neurons with Cat\u2019s Eyes: A Synthetic Strain of alpha-Synuclein Fibrils Seeding Neuronal Intranuclear Inclusions. Biomolecules 12, 436 (2022).","journal-title":"Biomolecules"},{"key":"822_CR52","doi-asserted-by":"publisher","first-page":"e0116473","DOI":"10.1371\/journal.pone.0116473","volume":"10","author":"C Betzer","year":"2015","unstructured":"Betzer, C. et al. Identification of synaptosomal proteins binding to monomeric and oligomeric alpha-synuclein. PLoS One 10, e0116473 (2015).","journal-title":"PLoS One"},{"key":"822_CR53","doi-asserted-by":"publisher","first-page":"6019","DOI":"10.1016\/j.vaccine.2020.07.016","volume":"38","author":"I Lieknina","year":"2020","unstructured":"Lieknina, I. et al. Novel ssRNA phage VLP platform for displaying foreign epitopes by genetic fusion. Vaccine 38, 6019\u20136026 (2020).","journal-title":"Vaccine"},{"key":"822_CR54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1107\/S0907444911007773","volume":"67","author":"C Vonrhein","year":"2011","unstructured":"Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr D. Biol. Crystallogr 67, 293\u2013302 (2011).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"822_CR55","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr"},{"key":"822_CR56","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr D. Biol. Crystallogr 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"822_CR57","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1107\/S0907444996012255","volume":"53","author":"GN Murshudov","year":"1997","unstructured":"Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D. Biol. Crystallogr. 53, 240\u2013255 (1997).","journal-title":"Acta Crystallogr D. Biol. Crystallogr."},{"key":"822_CR58","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/prot.20449","volume":"59","author":"WF Vranken","year":"2005","unstructured":"Vranken, W. F. et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 59, 687\u2013696 (2005).","journal-title":"Proteins"},{"key":"822_CR59","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1074\/jbc.M114.610527","volume":"290","author":"R Porcari","year":"2015","unstructured":"Porcari, R. et al. The H50Q mutation induces a 10-fold decrease in the solubility of alpha-synuclein. J. Biol. Chem. 290, 2395\u20132404 (2015).","journal-title":"J. Biol. Chem."},{"key":"822_CR60","doi-asserted-by":"publisher","first-page":"pgac259","DOI":"10.1093\/pnasnexus\/pgac259","volume":"1","author":"L Reimer","year":"2022","unstructured":"Reimer, L. et al. Protein kinase R dependent phosphorylation of alpha-synuclein regulates its membrane binding and aggregation. PNAS Nexus 1, pgac259 (2022).","journal-title":"PNAS Nexus"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00822-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00822-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00822-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T04:48:06Z","timestamp":1730090886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00822-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,27]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["822"],"URL":"https:\/\/doi.org\/10.1038\/s41531-024-00822-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.10.27.564328","asserted-by":"object"}]},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,27]]},"assertion":[{"value":"26 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}